BR0010948A - Uso de 1-[4-(5-cianoindol-3-il)butil]-4-(2-carbamoil-benzofura n-5-il)-piperazina e seus sais fisiologicamente aceitáveis - Google Patents

Uso de 1-[4-(5-cianoindol-3-il)butil]-4-(2-carbamoil-benzofura n-5-il)-piperazina e seus sais fisiologicamente aceitáveis

Info

Publication number
BR0010948A
BR0010948A BR0010948-7A BR0010948A BR0010948A BR 0010948 A BR0010948 A BR 0010948A BR 0010948 A BR0010948 A BR 0010948A BR 0010948 A BR0010948 A BR 0010948A
Authority
BR
Brazil
Prior art keywords
disorders
cyanoindol
carbamoyl
butyl
physiologically acceptable
Prior art date
Application number
BR0010948-7A
Other languages
English (en)
Inventor
Gerd Bartoszyk
Christoph Seyfried
Christoph Van Amsterdam
Henning Boettcher
Ewen Sedman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0010948(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0010948A publication Critical patent/BR0010948A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE 1-[4-(5-CIANOINDOL-3-IL)BUTIL]-4-(2-CARBAMOIL-BENZOFURA N-5-IL)-PIPERAZINA E SEUS SAIS FISIOLOGICAMENTE ACEITáVEIS". 1-[4-(5-cianoindol-3-il)butil]-4-(2-carbamoil-benzofuran-5-il)-plperazina ou um sal fisiologicamente aceitável do mesmo é usado para a fabricação de um medicamento para o tratamento de distúrbios subtipos de distúrbios da ansiedade escolhidos entre os subtipos de distúrbio do pânico com ou sem agorafobia, agorafobia, distúrbios do âmbito obsessivocompulsivo, fobia social, distúrbio de estresse pós-traumático, indicação de estresse agudo ou distúrbio da ansiedade generalizado, distúrbios bipolares, mania, demência, distúrbios relacionados com substâncias, disfunções sexuais, distúrbios alimentares, obesidade, anorexia e fibromialgia. Um sal preferencial é cioridrato de 1-[4-(5-cianoindoi-3-il)butiil-4-(2-carbamoil-benzofuran-5-il)-piperazina .
BR0010948-7A 1999-05-27 2000-05-16 Uso de 1-[4-(5-cianoindol-3-il)butil]-4-(2-carbamoil-benzofura n-5-il)-piperazina e seus sais fisiologicamente aceitáveis BR0010948A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27
PCT/EP2000/004376 WO2000072832A2 (en) 1999-05-27 2000-05-16 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts

Publications (1)

Publication Number Publication Date
BR0010948A true BR0010948A (pt) 2002-04-23

Family

ID=8238153

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010948-7A BR0010948A (pt) 1999-05-27 2000-05-16 Uso de 1-[4-(5-cianoindol-3-il)butil]-4-(2-carbamoil-benzofura n-5-il)-piperazina e seus sais fisiologicamente aceitáveis

Country Status (31)

Country Link
US (4) US6900212B1 (pt)
EP (3) EP1185272B1 (pt)
JP (2) JP4884588B2 (pt)
KR (1) KR100683367B1 (pt)
CN (3) CN101869565A (pt)
AR (1) AR024112A1 (pt)
AT (3) ATE337008T1 (pt)
AU (1) AU771778B2 (pt)
BR (1) BR0010948A (pt)
CA (3) CA2694866A1 (pt)
CY (2) CY1105750T1 (pt)
CZ (1) CZ295623B6 (pt)
DE (3) DE60042710D1 (pt)
DK (3) DK1185272T3 (pt)
ES (3) ES2271707T3 (pt)
HK (1) HK1048444B (pt)
HU (1) HU229059B1 (pt)
IL (2) IL146707A0 (pt)
MX (1) MXPA01012172A (pt)
MY (1) MY135627A (pt)
NO (2) NO322120B1 (pt)
PL (3) PL200490B1 (pt)
PT (3) PT1185272E (pt)
RU (1) RU2237477C2 (pt)
SI (2) SI1410800T1 (pt)
SK (1) SK287851B6 (pt)
TR (1) TR200103361T2 (pt)
TW (1) TW518218B (pt)
UA (1) UA74337C2 (pt)
WO (1) WO2000072832A2 (pt)
ZA (1) ZA200110485B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) * 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
WO2004082686A2 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
MX2008015226A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Derivados de 1,3,4-oxadiazol como inhibidores de dgat1.
BRPI0821274A2 (pt) 2007-12-20 2017-06-13 Astrazeneca Ab composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
EP2443096A1 (en) 2009-06-19 2012-04-25 AstraZeneca AB Pyrazine carboxamides as inhibitors of dgat1
RU2556585C2 (ru) 2009-11-06 2015-07-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома дефицита внимания и гиперактивности
CN102781436B (zh) 2009-11-06 2014-01-08 爱思开生物制药株式会社 纤维肌痛综合征的治疗方法
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
EP2688884A1 (en) 2011-03-20 2014-01-29 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP2861586A4 (en) 2012-06-13 2015-11-11 Apotex Inc FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
EP3598971B1 (en) 2013-01-22 2024-03-20 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
EP3297619B1 (en) * 2015-05-22 2022-07-06 Vistagen Therapeutics, Inc. Therapeutic uses of l-4-chlorokynurenine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1291660A3 (en) * 2001-09-11 2003-05-28 Koyo Seiko Co., Ltd. Magnetic pulser ring, magnetizing device and method, and bearing unit having a magnetic pulser ring
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
DK1410800T3 (da) 2006-12-27
MY135627A (en) 2008-05-30
ES2271707T3 (es) 2007-04-16
PL352373A1 (en) 2003-08-25
UA74337C2 (uk) 2005-12-15
IL146707A0 (en) 2002-07-25
PL199650B1 (pl) 2008-10-31
EP1736158A2 (en) 2006-12-27
KR20020008847A (ko) 2002-01-31
HK1048444A1 (en) 2003-04-04
PT1410800E (pt) 2007-01-31
EP1736158A3 (en) 2007-01-03
US7642261B2 (en) 2010-01-05
CY1105750T1 (el) 2010-12-22
ZA200110485B (en) 2003-06-30
AU771778B2 (en) 2004-04-01
DE60009697D1 (de) 2004-05-13
KR100683367B1 (ko) 2007-02-15
EP1185272B1 (en) 2004-04-07
AU5066300A (en) 2000-12-18
US20080119484A1 (en) 2008-05-22
JP2011148799A (ja) 2011-08-04
PT1185272E (pt) 2004-08-31
DE60009697T2 (de) 2005-04-14
HU229059B1 (en) 2013-07-29
DK1185272T3 (da) 2004-08-09
CN1679577A (zh) 2005-10-12
DE60030338T2 (de) 2007-08-16
NO20015746L (no) 2001-11-26
SK16462001A3 (sk) 2002-02-05
DE60042710D1 (de) 2009-09-17
ATE263564T1 (de) 2004-04-15
CY1109472T1 (el) 2012-05-23
WO2000072832A3 (en) 2001-12-20
WO2000072832A2 (en) 2000-12-07
DE60030338D1 (de) 2006-10-05
CA2615271A1 (en) 2000-12-07
ATE438399T1 (de) 2009-08-15
ES2330774T3 (es) 2009-12-15
CA2372668C (en) 2009-11-03
JP4884588B2 (ja) 2012-02-29
PL199516B1 (pl) 2008-09-30
TW518218B (en) 2003-01-21
NO20061562L (no) 2001-11-26
US7371756B2 (en) 2008-05-13
SI1410800T1 (sl) 2007-02-28
CZ295623B6 (cs) 2005-09-14
CA2694866A1 (en) 2000-12-07
RU2237477C2 (ru) 2004-10-10
NO324230B1 (no) 2007-09-10
EP1410800B1 (en) 2006-08-23
PT1736158E (pt) 2009-11-11
AR024112A1 (es) 2002-09-04
DK1736158T3 (da) 2009-11-02
CN101869565A (zh) 2010-10-27
NO20015746D0 (no) 2001-11-26
PL200490B1 (pl) 2009-01-30
HK1048444B (zh) 2005-12-09
US20100063062A1 (en) 2010-03-11
TR200103361T2 (tr) 2002-05-21
HUP0201275A3 (en) 2004-04-28
HUP0201275A2 (en) 2002-08-28
CA2372668A1 (en) 2000-12-07
EP1736158B1 (en) 2009-08-05
NO322120B1 (no) 2006-08-14
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
JP2003500441A (ja) 2003-01-07
SI1185272T1 (en) 2004-12-31
ATE337008T1 (de) 2006-09-15
MXPA01012172A (es) 2002-07-22
SK287851B6 (sk) 2012-01-04
CA2615271C (en) 2011-02-15
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
EP1410800A1 (en) 2004-04-21
CZ20014226A3 (cs) 2002-03-13
CN1361692A (zh) 2002-07-31
IL146707A (en) 2007-06-03
CN1198618C (zh) 2005-04-27

Similar Documents

Publication Publication Date Title
BR0010948A (pt) Uso de 1-[4-(5-cianoindol-3-il)butil]-4-(2-carbamoil-benzofura n-5-il)-piperazina e seus sais fisiologicamente aceitáveis
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
DE69424893D1 (de) Enantiomere von 1-[(4-Chlorophenyl)phenylmethyl]-4-[(4-Methylphenyl)sulfonyl]piperazin
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BR0315681A (pt) Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável
RU2001133342A (ru) Новое применение 1[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина и его физиологически приемлемых солей
EE200300167A (et) Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks
DK1263504T3 (da) Anvendelse af forbindelser med 5-HT1A aktivitet, som er anvendelige til behandling af lidelser i den ydre retina
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
NO973857D0 (no) 1-aryl-2-acylamino-etanforbindelser og deres anvnedelse som neurokinin-, spesielt neurokinin-1-antagonister
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
BR0314843A (pt) Novo composto
DE69811248T2 (de) Verwendung eines 5ht2 rezeptor-antagonisten zur behandlung von schlafapnoe
NZ513851A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
BR0009080A (pt) Método de tratamento da apnéia do sono
BR9910696A (pt) Composições farmacêuticas
BR9713514A (pt) Novo uso de creatina
BR0109119A (pt) Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometil]-cr omano e seus sais fisiologicamente aceitáveis
BR0009704A (pt) Utilização do osanetant para a preparação de medicamentos úteis no tratamento das perturbações do humor
BR9808234A (pt) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas para a produção de uma composição farmacêutica para o tratamento de distúrbios do sono
TH57869B (th) การใช้ในทางใหม่ของ 1-[4-(5-ไซยาโนอินดอล-3-อิล)บิวทิล]-4-(2-คาร์บาโมอิลเบนโซฟูแรน-5-อิล)พิเพอราซีน และเกลือของสารดังกล่าวซึ่งเป็นที่ยอมรับทางสรีรวิทยา
DE50210727D1 (de) Verwendung von arzneimitteln enthaltend n, n'-disubstituierte piperazin-verbindungen
RU2005140516A (ru) Применение ингибитора тирозинкиназы для лечения диабета
EP0760013A4 (en) TREATMENT OF INFLUENZA VIRUS INFECTION WITH HEMAGGLUTININ ACYLATION / PALMITYLATION INHIBITING ANTIVIRALS
BR0013921A (pt) Composições farmacêuticas para tratamento de psorìase

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]